Targeting Chromosomal Instability and Tumour Heterogeneity in HER2-Positive Breast Cancer

被引:44
|
作者
Burrell, Rebecca A. [1 ]
Juul, Nicolai [2 ]
Johnston, Stephen R. [3 ]
Reis-Filho, Jorge S. [4 ]
Szallasi, Zoltan [2 ,5 ]
Swanton, Charles [1 ,3 ]
机构
[1] London Res Inst, Translat Canc Therapeut Lab, London WC2A 3PX, England
[2] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark
[3] Royal Marsden Hosp, Breast Unit, Dept Med, Sutton SM2 5PT, Surrey, England
[4] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
[5] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol CHIP HST, Childrens Hosp Informat Program, Boston, MA 02115 USA
关键词
CHROMOSOMAL INSTABILITY; HER2; BREAST CANCER; DRUG RESISTANCE; TUMOUR HETEROGENEITY; MICROTUBULE; CEP17; SPINDLE ASSEMBLY CHECKPOINT; TAXOL-INDUCED APOPTOSIS; IN-SITU HYBRIDIZATION; PHASE-II TRIAL; MITOTIC CHECKPOINT; 1ST-LINE TREATMENT; INTRATUMORAL HETEROGENEITY; RETROSPECTIVE ANALYSIS; KARYOTYPIC COMPLEXITY; ADJUVANT CHEMOTHERAPY;
D O I
10.1002/jcb.22781
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chromosomal instability (CIN) is a common cause of tumour heterogeneity and poor prognosis in solid tumours and describes cell-cell variation in chromosome structure or number across a tumour population. In this article we consider evidence suggesting that CIN may be targeted and may influence response to distinct chemotherapy regimens, using HER2-positive breast cancer as an example. Pre-clinical models have indicated a role for HER2 signalling in initiating CIN and defective cell-cycle control, and evidence suggests that HER2-targeting may attenuate this process. Anthracyclines and platinum agents may target tumours with distinct patterns of karyotypic complexity, whereas taxanes may have preferential activity in tumours with relative chromosomal stability. A greater understanding of karyotypic complexity and identification of methods to directly examine and target CIN may support novel strategies to improve outcome in cancer. J. Cell. Biochem. 111: 782-790, 2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:782 / 790
页数:9
相关论文
共 50 条
  • [31] Adjuvant Therapy for HER2-Positive Breast Cancer
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (12): : 1134 - 1134
  • [33] Optimizing Treatment of HER2-Positive Breast Cancer
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 649 - 651
  • [34] Hormonotherapy in patients with HER2-positive breast cancer
    Debska, Sylwia
    Potemski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2010, 6 (06): : 301 - 310
  • [35] Neoadjuvant treatment for HER2-positive breast cancer
    Takada, Masahiro
    Toi, Masakazu
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [36] Brain metastases in HER2-positive breast cancer
    Lin, Nancy U.
    LANCET ONCOLOGY, 2013, 14 (03): : 185 - 186
  • [37] Cardiotoxicity in HER2-positive breast cancer patients
    Gonciar, Diana
    Mocan, Lucian
    Zlibut, Alexandru
    Mocan, Teodora
    Agoston-Coldea, Lucia
    HEART FAILURE REVIEWS, 2021, 26 (04) : 919 - 935
  • [38] Is there a role for immunotherapy in HER2-positive breast cancer?
    Holgado, Esther
    Perez-Garcia, Jose
    Gion, Maria
    Cortes, Javier
    NPJ BREAST CANCER, 2018, 4
  • [39] Adjuvant treatment for HER2-positive breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2015, 16 (02): : E59 - E59
  • [40] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679